Development and validation of a predictive model for chemotherapy-associated thrombosis.

By A. Khorana, N. Kuderer, E. Culakova, G. Lyman, C. Francis. Blood, 2008

2,076 citations recorded by the source corpus.

Subfields: Emergency Medical Services, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/e20a854ce9492e03e6b26d20c382ff3a2d32c02e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. H. Versteeg
2. S. Konstantinides

In Internal Medicine

1. G. Agnelli
2. S. Konstantinides
3. H. Büller

Citations in the corpus

• Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, background): “Several randomized trials have demonstrated a significant thromboprophylactic effect of lowmolecular-weight heparins (LMWH) in ambulatory cancer patients who are receiving chemotherapy.(166,167) However, routine thromboprophylaxis is currently not recommended for ambulatory cancer patients by ASCO b”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “For example, in the International Cooperative Pulmonary Embolism Registry (ICOPER), age .70 years, systolic BP ,90 mm Hg, respiratory rate .20 breaths/min, cancer, chronic heart failure and chronic obstructive pulmonary disease (COPD), were all identified as prognostic factors.48 In the Registro Inf”
• Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013, methodology): “Data adapted.(88) Abbreviation: VTE, venous thromboembolism.”
• Epidemiology of cancer-associated venous thrombosis. (2013, methodology): “Such a risk assessment model has been developed by Khorana et al.59 In a randomly selected development cohort of 2701 cancer patients initiating a new chemotherapy regimen, baseline clinical and laboratory risk factors for venous thrombosis were included in a risk model, which was validated in an in”
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “Cancer is a well-recognized predisposing factor for VTE.”
• American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, background): “Treatment or prophylaxis of VTE for patients with cancer must always balance the risk of recurrent VTE events with the increased risk of anticoagulant-related bleeding and take into consideration the consequences of these outcomes (including mortality, financial cost, quality of life), as well as pa”
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “For example, in the International Cooperative Pulmonary Embolism Registry (ICOPER), age .70 years, systolic BP ,90 mm Hg, respiratory rate .20 breaths/min, cancer, chronic heart failure and chronic obstructive pulmonary disease (COPD), were all identified as prognostic factors.48 In the Registro Inf”